Rationale and design of ProUrokinase in Mild IsChemic strokE (PUMICE): a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial
Open Access
- 31 January 2024
- journal article
- research article
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (6) , 715-722
Abstract
Background and purpose Recombinant human prourokinase (rhPro-UK) is a new generation of specific plasminogen activator, that is non-inferior to alteplase in acute ischemic stroke. We aimed to investigate the efficacy and safety of rhPro-UK compared with standard medical treatment in acute mild ischemic stroke within 4.5 hours of symptom onset. Methods and design Prourokinase in mild ischemic stroke is a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial. Patients who had an acute ischemic stroke within 4.5 hours from symptom onset and with baseline National Institutes of Health Stroke Scale (NIHSS) score ≤ 5 will be recruited. Patients will be randomly assigned (1:1) to receive intravenous rhPro-UK (35 mg) or standard medical treatment. The follow-up duration will be 90 days. The calculated sample size is 1446. Study outcomes Primary efficacy outcome is an excellent functional outcome, defined as a modified Rankin Scale (mRS) score ≤ 1 at 90 days. Secondary efficacy outcomes include ordinal distribution of mRS at 90 days, mRS score ≤ 2 at 90 days, early neurological improvement at 24 hours (a decrease of NIHSS score ≥ 4 points compared with baseline or NIHSS score ≤ 1 point), Barthel index of 75–100 points at 90 days, quality of life at 90 days, and activities of daily living at 90 days. Safety outcomes are symptomatic intracranial haemorrhage within 36 hours, mortality at 90 days, moderate and severe systematic bleeding at 90 days, and adverse events/serious adverse events within 90 days. Discussion This large phase III randomised clinical trial will answer the question of whether thrombolysis is beneficial for acute mild ischemic stroke, and may provide evidence for rhPro-UK in patients had an acute mild ischemic stroke within 4.5 hours of symptom onset. Trial registration number NCT05507645Keywords
Funding Information
- TASLY BIOPHARMACEUTICALS CO.,LTD.
This publication has 20 references indexed in Scilit:
- Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke OnsetJAMA Network Open, 2023
- Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic StrokeJAMA, 2023
- Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trialThe Lancet, 2023
- Efficacy and Safety of Recombinant Human Prourokinase in Acute Ischemic Stroke: A Phase IIa Randomized Clinical TrialTranslational Stroke Research, 2022
- Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic AttackJAMA Neurology, 2019
- Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic DeficitsJAMA, 2018
- One-year outcomes and secondary prevention in patients after acute minor stroke: results from the China National Stroke RegistryNeurological Research, 2017
- Outcomes in Mild Acute Ischemic Stroke Treated With Intravenous ThrombolysisJAMA Neurology, 2015
- Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsThe Lancet, 2014
- Recombinant Tissue Plasminogen Activator for Minor Strokes: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study ExperienceAnnals of Emergency Medicine, 2005